Meta-Analysis
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2013; 19(35): 5917-5924
Published online Sep 21, 2013. doi: 10.3748/wjg.v19.i35.5917
Table 1 Summary of the general characteristics of the included studies regarding vitamin D and hepatitis C virus (mean ± SD)
StudyCountryMean age (yr)Sample SizeDesign25(OH)D measurementBasal mean vitamin D levels (ng/mL)
Nimer et al[26]IsraelTreated: 48 ± 14Treated: 20 HCV infected individualsProspective randomized studyRadioimmunoassay (Diasorin)Treated: 20 ± 8
Non treated: 45 ± 10Non treated: 30 HCV infected individualsNon treated: 19 ± 6
Milazzo et al[25]Italy4593 HIV/HCVRetrospective case-control study (clinical samples)Radioimmunoassay (IDS)Cases: 23.1 (15.3-35.3)
Abu-Mouch et al[27]IsraelTreated: 47 ± 11Treated: 36 HCV infected individualsProspective randomized studyRadioimmunoassay (Diasorin)Treated: 19 ± 6
Non treated: 49 ± 7Non treated: 36 HCV infected individualsNon treated: 20.5 ± 9
Bitetto et al[20]ItalyTreated: 56 (42-61)Treated: 15 HCV infected individualsProspective randomized studyChemiluminescence immunoassay (Diasorin)NA
Non treated: 52 (23-67)Non treated: 27 HCV infected individuals
Soumekh et al[28]United StatesNA88 HIV/HCV infected individualsProspective study (clinical samples)Chemiluminescence immunoassay (Diasorin)NA
Reiberg et al[29]Austria3884 HIV/HCV infected individualsCohort (clinical sample)NA21.9 ± 13.8
Jazwinski et al[23]United StatesNA82 HCV infected individualsCohort (clinical sample)Chemiluminescence immunoassay (Diasorin)NA
Lange et al[18]Germany45468 HCV infected individualsCohort (clinical sample)Radioimmunoassay (Diasorin)17 (3-80)
Terrier et al[22]France39.5189 HIV/HCV infected individualsCohort (clinical samples)Radioimmunoassay (Diasorin)18.5 ± 9.8
Bitetto et al[21]Italy47211 HCV individualsCohort (clinical samples)Chemiluminescence immunoassay (Diasorin)20.7 (2.1-59.6)
Petta et al[17]Italy52Cases: 196 HCV infected individualsTransversal case-control (clinic and community sample)HPLC25.0 ± 9.9